Cytophage Technologies Ltd.
CYTO.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Net Income | -798.70K | -911.20K | -3.18M | -762.70K | |
| Total Depreciation and Amortization | 130.20K | 126.60K | 132.10K | 84.80K | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -6.60K | -18.40K | 1.98M | 35.80K | |
| Change in Net Operating Assets | 40.00K | 44.00K | -501.30K | 24.60K | |
| Cash from Operations | -635.20K | -759.10K | -1.56M | -617.50K | |
| Capital Expenditure | -266.60K | -569.20K | -46.20K | -26.80K | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 0.00 | 0.00 | 5.82M | -- | |
| Cash from Investing | -266.60K | -569.20K | 5.78M | -26.80K | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -74.60K | -100.60K | -113.60K | -40.30K | |
| Issuance of Common Stock | 0.00 | 5.00K | 2.50M | 216.00K | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 0.00 | 0.00 | -2.53M | 0.00 | |
| Cash from Financing | -54.70K | -69.90K | -105.60K | 131.00K | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -956.50K | -1.40M | 4.11M | -513.30K | |